ICER dials up recommended price range for Eisai's Leqembi—but still calls for sizable discount

Influential U.S. drug pricing research group the Institute for Clinical and Economic Review (ICER) has updated its assessment of Eisai’s new Alzheimer's disease drug Leqembi. In the wake of a rival drug's rejection, the agency supports a slightly higher price tag for the Eisai medicine than it had previously proposed.